Introduction to Pluripotent Stem Cells L5
30 Questions
0 Views

Choose a study mode

Play Quiz
Study Flashcards
Spaced Repetition
Chat to lesson

Podcast

Play an AI-generated podcast conversation about this lesson

Questions and Answers

Which of the following are pluripotent stem cells?

  • Cells that don’t have the ability for self renewal except placenta
  • Cells has the potential to form only multiple adult types
  • Cells has the potential to differentiate into any adult cell type forming an entire organism (correct)
  • Cells that has limited potential to form all different cell types

    • Important limitation of using cloned ESCs (SCNT-ESCs).

  • Produced limited number of cell types
  • Destruction of human embryos in the laboratory (correct)
  • Immune rejection
  • Difficult to grow and culture

    • Mesenchymal stem cells are examples of:

  • Pluripotent SC
  • Totipotent SC
  • Multipotent SC (correct)
  • Induced pluripotent SC

    • Which of the following is a type of Multipotent stem cells?

    <p>Hematopoietic SC</p> Signup and view all the answers

    What are the classifications of stem cells mentioned in the text?

    <p>Embryonic Stem Cell, Adult stem cells, Induced Pluripotent Stem Cell (iPS) cells</p> Signup and view all the answers

    What is the main function of a stem cell within the body?

    <p>Continuously divide and give rise to new copy of itself (self-renew), differentiate into various kinds of cells/tissues</p> Signup and view all the answers

    What are the triggers for differentiation of stem cells mentioned in the text?

    <p>Internal signals (specific genes), External signals (Growth factors, cytokines like: TGF-B &amp; FGF)</p> Signup and view all the answers

    Who presented the lecture on Introduction to Pluripotent Stem cells?

    <p>Dr. Amer Mahmoud and Dr. Mona Al Safadi</p> Signup and view all the answers

    What is the promise of Stem Cell Technology mentioned in the text?

    <p>Continuous repair of defective cell types and regeneration of tissues</p> Signup and view all the answers

    What are the different approaches for isolation of pluripotent stem cells mentioned in the text?

    <p>Isolation from embryos, reprogramming adult cells, extraction from specific tissues</p> Signup and view all the answers

    Where can we find Embryonic Stem Cells according to the text?

    <p>Embryos at early developmental stage</p> Signup and view all the answers

    What are the unique characteristics of stem cells as mentioned in the text?

    <p>Unlimited self-renewal and differentiation into various kinds of cells/tissues</p> Signup and view all the answers

    Who recommended watching two videos PART 1 & PART 2 according to the text?

    <p>Dr. Amer Mahmoud and Dr. Mona Al Safadi</p> Signup and view all the answers

    What was emphasized as a main function within the body for stem cells according to the text?

    <p>Continuous repair of defective cell types and regeneration of tissues.</p> Signup and view all the answers

    Which type of stem cells can differentiate into cells of the 3 germ layers?

    <p>Pluripotent stem cells</p> Signup and view all the answers

    What did Shinya Yamanaka develop in 2006 to potentially avoid the use of embryos in stem cell research?

    <p>Reprogramming ordinary adult cells into iPSCs</p> Signup and view all the answers

    What is the main source of totipotent stem cells?

    <p>Zygote at 1-3 days</p> Signup and view all the answers

    What was the first mammal cloned from an adult somatic cell using somatic cell nuclear transfer (SCNT)?

    <p>A sheep (Dolly)</p> Signup and view all the answers

    Which factor(s) are involved in reprogramming somatic cells into induced pluripotent stem cells (iPSCs)?

    <p>(Oct4, Sox2, Klf4, and c-Myc)</p> Signup and view all the answers

    What is the main challenge in the application of induced pluripotent stem cells (iPSCs) as a potential patient-specific cell therapy?

    <p>Ensuring their safety and effectiveness</p> Signup and view all the answers

    What are the three classifications of stem cells mentioned in the text?

    <p>Embryonic, adult, induced pluripotent</p> Signup and view all the answers

    What is the main function of a stem cell within the body?

    <p>Tissue repair and regeneration</p> Signup and view all the answers

    Who presented the lecture on Introduction to Pluripotent Stem Cells?

    <p>Dr. Amer Mahmoud</p> Signup and view all the answers

    In which year was the first medical treatment using human embryonic stem cells carried out?

    <p>2010</p> Signup and view all the answers

    What was the first mammal cloned from an adult somatic cell using somatic cell nuclear transfer (SCNT)?

    <p>Dolly the sheep</p> Signup and view all the answers

    What were the transcription factors involved in reprogramming somatic cells into induced pluripotent stem cells (iPSCs)?

    <p>OCT4, SOX2, NANOG, Lin28</p> Signup and view all the answers

    Which of the following is a main challenge in the application of induced pluripotent stem cells (iPSCs) as a potential patient-specific cell therapy?

    <p>Potential immune rejection</p> Signup and view all the answers

    What are the unique characteristics of mesenchymal stem cells?

    <p>Ability to differentiate into multiple cell types</p> Signup and view all the answers

    Which factor(s) are involved in reprogramming somatic cells into induced pluripotent stem cells (iPSCs)?

    <p>Oct4, Sox2, Klf4, c-Myc</p> Signup and view all the answers

    What is the main source of totipotent stem cells?

    <p>Zygote</p> Signup and view all the answers

    Study Notes

    • Stem cells are classified based on their potency and source

    • Totipotent stem cells: (1) Zygote at 1-3 days, (2) Multipotent, (3) Extraembryonic: placenta and umbilical cord, (4) Form embryo and placenta, (5) No immune rejection or ethical concerns

    • Pluripotent stem cells: (1) Descendants of totipotent cells, (2) Differentiate into cells of the 3 germ layers, (3) Found in specific mature body tissues, umbilical cord, and placenta after birth, (4) Can form embryo, (5) Isolated from developing embryos' different tissues

    • Multipotent stem cells: (1) Produce cells of closely related cells, (2) Sources: bone marrow, placenta cord, mesenchymal, (3) Family stem cells

    • Oligopotent stem cells: Differentiate into only a few cells, such as lymphoid or myeloid stem cells

    • Unipotent stem cells: Produce only one cell type, such as muscle stem cells

    • Embryonic stem cells: (1) Pluripotent, (2) Large numbers can be harvested, (3) May cause immune rejection and ethical concerns, (4) Sources: IVF embryos, aborted embryos, cloned embryos

    • Stem cell technologies: (1) Cloning technologies: reproductive and molecular cloning, (2) Induced pluripotent stem cells (iPSCs): new way to potentially avoid the use of embryos, disease-specific stem cell lines, promise and potential pitfalls

    • In 1981, Marin Evans identified embryonic stem cells in mice, and in 1998, James Thomson and John Gearhart isolated human embryonic stem cells

    • In 2001, the Bush controversy, with ethical concerns around the use of human embryonic stem cells

    • In 2006, Shinya Yamanaka reprogrammed ordinary adult cells to form iPSCs

    • In 2010, the first medical treatment using human embryonic stem cells: spinal injury

    • In 2012, the first medical treatment using human embryonic stem cells: blindness

    • In 2014, human trials using iPSCs

    • Somatic cell nuclear transfer (SCNT) cloning: process of creating an embryo from an adult somatic cell, Dolly the sheep was the first mammal cloned from an adult somatic cell using SCNT

    • Therapeutic cloning: use of stem cells to correct diseases and other health problems, generates embryonic stem cells with the same genetic material as the patient, used for regenerative medicine

    • Induced pluripotent stem cells (iPSCs): somatic cells (such as skin cells) are genetically manipulated and returned to their embryonic state, generate virtually any cell type, characterized by the introduction of four transcription factors, Oct4, Sox2, Klf4, and c-Myc or Thomson factors: OCT4, SOX2, NANOG, and Lin28.

    • Difficulties in the application of iPSCs as a potential patient-specific cell therapy include characterizing their development potential and overcoming technical challenges.

    • In late 2006, Takahashi and Yamanaka reported the stimulation of cells from adult and embryonic origin to pluripotent stem cells called iPSCs.

    • The method was described by Yamanaka, who genetically manipulated skin cells (fibroblasts) of laboratory mice and returned them to their embryonic state.

    • iPSCs are somatic cells that have been reprogrammed to a pluripotent state (embryonic stem cell-like state).

    • The first experimental application of iPSCs was done on a mouse, and the process involved taking skin cells from a sickle-cell model mouse, differentiating them into pluripotent stem cells, and then into hematopoietic cells. The produced cells were then transfused back into the sick mouse, which recovered.

    • The generation of embryonic stem cells was first accomplished in 1995 by Dr. James Thomson, who derived them from a 4-5 day old embryo (blastocyst).

    • The blastocyst was composed of two parts: trophoblast and inner cell mass.

    • The inner cell mass was further developed into embryonic stem cells.

    • The ethical concerns around the use of human embryonic stem cells led to controversy in 2001.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • iPSCs have the potential to generate virtually any cell type and offer the promise of personalized regenerative medicine.

    • However, several difficulties must be overcome before they can be considered as a potential patient-specific cell therapy.

    • Experimental application of iPSCs in a mouse involved taking skin cells from a sickle-cell model mouse, differentiating them into pluripotent stem cells, and then into hematopoietic cells. The produced cells were then transfused back into the sick mouse, and it recovered.

    • The rejection by the immune system had a very low chance to occur because the genetic material was originally from the mouse itself and not from a different one.

    • The ethical concerns around the use of human embryonic stem cells led to controversy in 2001.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • The reprogramming was accomplished by introducing four transcription factors, Oct4, Sox2, Klf4, and c-Myc.

    • The introduction of these factors allowed the somatic cells to be reprogrammed to a pluripotent state.

    • The process was similar to generating iPSCs from embryonic stem cells but did not involve the use of embryos.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • The technique involved introducing four transcription factors, Oct4, Sox2, Klf4, and c-Myc, into adult cells to reprogram them to a pluripotent state.

    • These iPSCs could then be used to generate virtually any cell type, offering the potential for personalized regenerative medicine.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • The development of iPSCs was a significant breakthrough in the field of regenerative medicine.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • The technique involved the introduction of four transcription factors, Oct4, Sox2, Klf4, and c-Myc, into adult cells to reprogram them to a pluripotent state.

    • The resulting iPSCs could be used to generate virtually any cell type, offering the potential for personalized regenerative medicine.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • The development of iPSCs was a significant breakthrough in the field of regenerative medicine.

    • The process of generating iPSCs was similar to generating embryonic stem cells but did not involve the use of embryos.

    • The technique involved the introduction of four transcription factors, Oct4, Sox2, Klf4, and c-Myc, into adult cells to reprogram them to a pluripotent state.

    • The resulting iPSCs could be used to generate virtually any cell type, offering the potential for personalized regenerative medicine.

    • The three-phase process of generating iPSCs involved the introduction of transcription factors, the reprogramming of the cells, and the subsequent differentiation of the cells into the desired cell type.

    • The process of generating iPSCs was not without challenges, and several difficulties must be overcome before they could be considered a viable patient-specific cell therapy.

    • The ethical concerns around the use of human embryonic stem cells were a

    • Stem cells are classified based on their potency and source

    • Totipotent stem cells: (1) Zygote at 1-3 days, (2) Multipotent, (3) Extraembryonic: placenta and umbilical cord, (4) Form embryo and placenta, (5) No immune rejection or ethical concerns

    • Pluripotent stem cells: (1) Descendants of totipotent cells, (2) Differentiate into cells of the 3 germ layers, (3) Found in specific mature body tissues, umbilical cord, and placenta after birth, (4) Can form embryo, (5) Isolated from developing embryos' different tissues

    • Multipotent stem cells: (1) Produce cells of closely related cells, (2) Sources: bone marrow, placenta cord, mesenchymal, (3) Family stem cells

    • Oligopotent stem cells: Differentiate into only a few cells, such as lymphoid or myeloid stem cells

    • Unipotent stem cells: Produce only one cell type, such as muscle stem cells

    • Embryonic stem cells: (1) Pluripotent, (2) Large numbers can be harvested, (3) May cause immune rejection and ethical concerns, (4) Sources: IVF embryos, aborted embryos, cloned embryos

    • Stem cell technologies: (1) Cloning technologies: reproductive and molecular cloning, (2) Induced pluripotent stem cells (iPSCs): new way to potentially avoid the use of embryos, disease-specific stem cell lines, promise and potential pitfalls

    • In 1981, Marin Evans identified embryonic stem cells in mice, and in 1998, James Thomson and John Gearhart isolated human embryonic stem cells

    • In 2001, the Bush controversy, with ethical concerns around the use of human embryonic stem cells

    • In 2006, Shinya Yamanaka reprogrammed ordinary adult cells to form iPSCs

    • In 2010, the first medical treatment using human embryonic stem cells: spinal injury

    • In 2012, the first medical treatment using human embryonic stem cells: blindness

    • In 2014, human trials using iPSCs

    • Somatic cell nuclear transfer (SCNT) cloning: process of creating an embryo from an adult somatic cell, Dolly the sheep was the first mammal cloned from an adult somatic cell using SCNT

    • Therapeutic cloning: use of stem cells to correct diseases and other health problems, generates embryonic stem cells with the same genetic material as the patient, used for regenerative medicine

    • Induced pluripotent stem cells (iPSCs): somatic cells (such as skin cells) are genetically manipulated and returned to their embryonic state, generate virtually any cell type, characterized by the introduction of four transcription factors, Oct4, Sox2, Klf4, and c-Myc or Thomson factors: OCT4, SOX2, NANOG, and Lin28.

    • Difficulties in the application of iPSCs as a potential patient-specific cell therapy include characterizing their development potential and overcoming technical challenges.

    • In late 2006, Takahashi and Yamanaka reported the stimulation of cells from adult and embryonic origin to pluripotent stem cells called iPSCs.

    • The method was described by Yamanaka, who genetically manipulated skin cells (fibroblasts) of laboratory mice and returned them to their embryonic state.

    • iPSCs are somatic cells that have been reprogrammed to a pluripotent state (embryonic stem cell-like state).

    • The first experimental application of iPSCs was done on a mouse, and the process involved taking skin cells from a sickle-cell model mouse, differentiating them into pluripotent stem cells, and then into hematopoietic cells. The produced cells were then transfused back into the sick mouse, which recovered.

    • The generation of embryonic stem cells was first accomplished in 1995 by Dr. James Thomson, who derived them from a 4-5 day old embryo (blastocyst).

    • The blastocyst was composed of two parts: trophoblast and inner cell mass.

    • The inner cell mass was further developed into embryonic stem cells.

    • The ethical concerns around the use of human embryonic stem cells led to controversy in 2001.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • iPSCs have the potential to generate virtually any cell type and offer the promise of personalized regenerative medicine.

    • However, several difficulties must be overcome before they can be considered as a potential patient-specific cell therapy.

    • Experimental application of iPSCs in a mouse involved taking skin cells from a sickle-cell model mouse, differentiating them into pluripotent stem cells, and then into hematopoietic cells. The produced cells were then transfused back into the sick mouse, and it recovered.

    • The rejection by the immune system had a very low chance to occur because the genetic material was originally from the mouse itself and not from a different one.

    • The ethical concerns around the use of human embryonic stem cells led to controversy in 2001.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • The reprogramming was accomplished by introducing four transcription factors, Oct4, Sox2, Klf4, and c-Myc.

    • The introduction of these factors allowed the somatic cells to be reprogrammed to a pluripotent state.

    • The process was similar to generating iPSCs from embryonic stem cells but did not involve the use of embryos.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • The technique involved introducing four transcription factors, Oct4, Sox2, Klf4, and c-Myc, into adult cells to reprogram them to a pluripotent state.

    • These iPSCs could then be used to generate virtually any cell type, offering the potential for personalized regenerative medicine.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • The development of iPSCs was a significant breakthrough in the field of regenerative medicine.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • In 2006, Shinya Yamanaka developed a new method to potentially avoid the use of embryos by reprogramming ordinary adult cells into iPSCs.

    • The technique involved the introduction of four transcription factors, Oct4, Sox2, Klf4, and c-Myc, into adult cells to reprogram them to a pluripotent state.

    • The resulting iPSCs could be used to generate virtually any cell type, offering the potential for personalized regenerative medicine.

    • The ethical concerns around the use of human embryonic stem cells were a major obstacle to their widespread use in research and medicine.

    • The development of iPSCs was a significant breakthrough in the field of regenerative medicine.

    • The process of generating iPSCs was similar to generating embryonic stem cells but did not involve the use of embryos.

    • The technique involved the introduction of four transcription factors, Oct4, Sox2, Klf4, and c-Myc, into adult cells to reprogram them to a pluripotent state.

    • The resulting iPSCs could be used to generate virtually any cell type, offering the potential for personalized regenerative medicine.

    • The three-phase process of generating iPSCs involved the introduction of transcription factors, the reprogramming of the cells, and the subsequent differentiation of the cells into the desired cell type.

    • The process of generating iPSCs was not without challenges, and several difficulties must be overcome before they could be considered a viable patient-specific cell therapy.

    • The ethical concerns around the use of human embryonic stem cells were a

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Related Documents

    Introduction to Pluripotent Stem Cells PDF

    Description

    Learn about the definition and main function of stem cells, their classifications, and the different approaches for isolating pluripotent stem cells.

    More Like This

    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser